disease

Seegene Launches STAgora, a New Platform for Infectious Disease AnalyticsSeegene Launches STAgora, a New Platform for Infectious Disease Analytics

Seegene Launches STAgora, a New Platform for Infectious Disease Analytics

Real-time analytics that empower clinical decision-making and pandemic preparednessGlobal unveiling at ADLM 2025 in Chicago to initiate business partnershipsPowered by AI…

2 weeks ago
Lilavati Hospital Doctors Save Life of 78-Year-Old Woman with Serious Heart DiseaseLilavati Hospital Doctors Save Life of 78-Year-Old Woman with Serious Heart Disease

Lilavati Hospital Doctors Save Life of 78-Year-Old Woman with Serious Heart Disease

India's First Successful Transcatheter Transatrial Mitral Valve Replacement Surgery Performed at Lilavati Hospital MUMBAI, India, June 17, 2025 /PRNewswire/ --…

4 weeks ago
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s diseaseRoche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease

Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage…

4 weeks ago
Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary diseaseInvestigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

4 weeks ago
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s DiseaseMerry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease

TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial…

1 month ago
Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer’s Disease.Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer’s Disease.

Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer’s Disease.

Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences,…

1 month ago
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathyERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal…

1 month ago